MIAMI, FL — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced that the ALS Association has awarded a Hoffman ALS Clinical Trial Award grant worth ~$1 million to study PAS-004 in ALS patients. The award was given...
research News
BUFFALO, NY – A new research paper was published in Volume 16 of Genes & Cancer on January 20, 2025, entitled, “Analysis of pathogenic variants in retinoblastoma reveals a potential gain of function mutation.” Researchers from Instituto de Física Universidad Autónoma de San Luis Potosí and Hospital Central “Ignacio Morones...
MIAMI, FLORIDA – In a study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, patients recently diagnosed with a common and aggressive form of acute myeloid leukemia reported having improved quality of life when a newly approved drug was part of...
Barcelona, Spain – Patients with advanced bladder cancer that had spread to other parts of the body (metastasised) have responded well in a phase I clinical trial of an investigational drug, TYRA-300. The drug targets changes in the FGFR3 gene that drive tumour growth in about 10%-20% of these patients....
Philadelphia, Pennsylvania – The majority of patients with metastatic colorectal cancer whose cancer did not progress during initial treatment with immune checkpoint inhibitors (ICIs) had no disease progression two years after discontinuing treatment. ICIs have proven effective against certain solid tumors, including those with a high microsatellite instability (MSI-H) or...
Aargau, Switzerland – In the treatment of cancer patients, irradiation can be adapted anew each day to the position of the tumour and conditions in the body. Researchers at the Paul Scherrer Institute PSI have now, for the first time, integrated such a workflow into everyday clinical practice in proton...
FRANKFURT, Germany – The term ‘leukemia’ encompasses various forms of blood cancer, including acute myeloid leukemia (AML). In AML, blood cells in the early stages – the stem cells and the precursor cells that develop out of them – degenerate. AML is the second most common leukemia in children, accounting...
PHILADELPHIA – Liver inflammation, a common side-effect of cancers elsewhere in the body, has long been associated with worse cancer outcomes and more recently associated with poor response to immunotherapy. Now, a team led by researchers from the Abramson Cancer Center and Perelman School of Medicine at the University of...
PHILADELPHIA – While breast cancer survival continues to improve, thanks to advances in detection and treatment, when breast cancer recurs – or returns after initial treatment – it is incurable. Currently, there is no way to predict who is most likely to experience a breast cancer recurrence, and for the...
PHILADELPHIA – Researchers at the University of Pennsylvania School of Medicine have uncovered variation around two genes that are associated with an increased risk of testicular cancer. Testicular cancer is the most common cancer among young men, and its incidence among non-Hispanic Caucasian men has doubled in the last 40...